Vera’s Atacicept Sets A New Efficacy Bar With Phase III Results In IgAN

First-In-Class Drug Exceeds Expectations

 
• By Mandy Jackson
  
Vera plans to develop atacicept in other indications, including kidney diseases beyond IgAN (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from Scrip